Linked Life Data

17314651

Source:http://linkedlifedata.com/resource/pubmed/id/17314651

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-2-22
pubmed:abstractText
Pamidronate treatment has been shown to improve outcome in osteogenesis imperfecta (OI); however, factors influencing outcome are unclear. The present study was conducted to evaluate the response to pamidronate therapy with special emphasis on factors influencing outcome. Twenty children with OI treated with pamidronate were evaluated in a prospective, open clinical trial. Pamidronate (9 mg x kg(-1) x yr) was administered intravenously at the age of 4.5 +/- 4.2 years for 2.9 +/- 0.7 years (range, 2-3.8 years). Treatment led to increase in bone mineral density (BMD) Z score by 0.7 +/- 0.3 every year resulting in significant improvement in BMD Z score (from -4.6 +/- 1.1 to -2.5 +/- 1.1, P<0.001). BMD Z score was within the reference range (>-2) in 9 subjects (45%) at the last follow-up as against none at initiation of treatment (P<0.001). Fracture rate decreased significantly during treatment (3.3 +/- 1.4 to 0.8 +/- 0.9, P<0.001) with 8 subjects (40%) having no fracture during the treatment period. Significantly greater proportion (88.2%) of children were able to walk at last follow-up compared with those at initiation of treatment (45.4%). Increase in BMD Z score and final BMD Z score was not influenced by age at initiation of treatment, duration of treatment, or initial BMD Z score. Treatment before infancy (n=7) was associated with higher final subjective score (6.3 +/- 0.5 vs 4.9 +/- 1.5, P=0.03). Our study reiterates the efficacy of pamidronate in OI. The poorer response of our subjects may be related to compromised calcium and vitamin D status.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0271-6798
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
225-7
pubmed:dateRevised
2009-8-24
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome.
pubmed:affiliation
Department of Endocrinology and Diabetes, Royal Children Hospital, Melbourne, Australia.
pubmed:publicationType
Journal Article, Clinical Trial